INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN ANGIOID STREAKS: Four-Year Follow-up

Autor: Franck Lalloum, Nathalie Puche, Mayer Srour, Gerard Mimoun, Giuseppe Querques, Eric H Souied, Julien Tilleul, Jennyfer Zerbib
Přispěvatelé: Tilleul, J, Mimoun, G, Querques, Giuseppe, Puche, N, Zerbib, J, Lalloum, F, Srour, M, Souied, Eh
Rok vydání: 2015
Předmět:
Adult
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Visual acuity
genetic structures
Visual Acuity
Angiogenesis Inhibitors
03 medical and health sciences
0302 clinical medicine
Ophthalmology
Ranibizumab
Medicine
Humans
In patient
030212 general & internal medicine
Fluorescein Angiography
Aged
Retrospective Studies
Aged
80 and over
medicine.diagnostic_test
business.industry
Retrospective cohort study
General Medicine
Middle Aged
Fluorescein angiography
medicine.disease
eye diseases
humanities
Choroidal Neovascularization
body regions
Angioid streaks
Choroidal neovascularization
Treatment Outcome
Intravitreal Injections
Retreatment
030221 ophthalmology & optometry
Angioid Streaks
Female
sense organs
medicine.symptom
Intravitreal ranibizumab
business
Tomography
Optical Coherence
medicine.drug
Follow-Up Studies
Zdroj: Retina (Philadelphia, Pa.). 36(3)
ISSN: 1539-2864
Popis: Purpose:To analyze retrospectively the efficacy of intravitreal ranibizumab injections for the management of choroidal neovascularization in patients with angioid streaks over a long term.Methods:In this nonrandomized, double-center, retrospective, interventional case series, a consecutive series of patients affected with choroidal neovascularization associated with angioid streaks were treated with intravitreal ranibizumab injections (0.5 mg/0.05 mL). Best-corrected visual acuity, fundus photography, optical coherence tomography, and fluorescein angiography were examined before and after treatment. The primary endpoint was the percentage of eyes with stable or improved visual acuity at the end of follow-up (loss of less than 3 Early Treatment Diabetic Retinopathy Study lines). Secondary endpoints were the percentage of eyes with stable or decreased macular thickness on optical coherence tomography (less than a 10% increase in macular thickness) and the percentage of eyes with persistent leakage on fluorescein angiography at the last observation carried forward.Results:Thirty-five eyes of 27 patients were treated with repeated intravitreal ranibizumab injections (mean of 9.9 7.2 injections, range 2-26) for a mean of 48.6 +/- 17.1 months (range 8-66). At the end of follow-up, best-corrected visual acuity was stabilized or improved in 22 of 35 eyes (62.9%). Macular thickness had stabilized or decreased in 16 of 35 eyes (45.7%). At the last follow-up examination, on fluorescein angiography, no further leakage was observed in 27 of 35 eyes (77.1%).Conclusion:In this large series of patients with choroidal neovascularization associated with angioid streaks followed for 4 years, ranibizumab injections allowed stabilization of best-corrected visual acuity in most eyes. Ranibizumab appear as an effective therapeutic option in CNV associated with angioid streaks over long time.
Databáze: OpenAIRE
Externí odkaz: